Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. (Vor Bio) (Nasdaq: VOR) is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through the development of telitacicept, a dual BAFF/APRIL fusion protein. The VOR news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Vor Bio’s telitacicept program and corporate strategy evolve over time.
According to recent announcements, Vor Bio’s news flow centers on late-stage clinical data for telitacicept in B‑cell–mediated autoimmune diseases, including generalized myasthenia gravis, Sjögren’s disease, systemic lupus erythematosus, and IgA nephropathy. The company and its collaborator RemeGen Co., Ltd. have reported Phase 3 results from studies conducted in China, including data presented at major medical meetings and in peer‑reviewed publications. These updates highlight efficacy endpoints, durability of response, and safety findings for telitacicept across multiple indications.
Investors following VOR news can also track capital markets activity, such as underwritten public offerings, private placements with institutional healthcare investors, and at‑the‑market equity sales programs disclosed in company press releases and Form 8‑K filings. Additional news items cover leadership and governance changes, including appointments to the Board of Directors and executive team roles like Chief Medical Officer, Chief Development Officer, and Chief Commercial Officer, which Vor Bio links to its late-stage development and potential commercialization plans.
Vor Bio’s participation in healthcare and investor conferences, including events such as the J.P. Morgan Healthcare Conference and other sector-focused meetings, is another recurring news theme. Visitors to this page can review updates on upcoming presentations, webcasts, and corporate slide decks referenced in SEC filings. For anyone monitoring VOR, the news feed offers a centralized view of clinical milestones, financing decisions, and strategic developments related to telitacicept and Vor Bio’s broader autoimmune disease focus.
Vor Bio (Nasdaq: VOR) has announced a dual fundraising initiative, pricing an underwritten offering and a private placement, aiming for combined gross proceeds of approximately $115.8 million. The underwritten offering includes 15,302,267 shares at $4.30 per share, expected to yield about $65.8 million, set to close around December 9, 2022. Concurrently, 11,627,907 shares will be sold privately to RA Capital for an additional $50 million. Proceeds will target clinical development and general corporate needs.
Vor Bio has announced promising initial clinical data from its Phase 1/2a trial of trem-cel (formerly VOR33) for acute myeloid leukemia (AML). The first patient's results indicate successful engraftment and maintenance of blood counts after treatment with Mylotarg. A total of 7.6 x106 CD34+ cells/kg were infused, achieving 100% donor chimerism and robust hematopoietic reconstitution. No adverse events related to Mylotarg were noted, highlighting the treatment's tolerability. A conference call discussing these developments is scheduled for December 7, 2022.
Vor Bio (Nasdaq: VOR), a clinical-stage company focusing on cell and genome engineering, will participate in several investor conferences. The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 9:30 am ET in New York. A fireside chat at the 5th Annual Evercore ISI HealthCONx Virtual Conference will occur on December 1 at 3:05 pm ET, followed by another fireside chat at The JMP Securities Hematology and Oncology Virtual Summit on December 6 at 1:20 pm ET. Webcasts of these events will be available on their website.
Vor Bio reported financial results for Q3 2022, showing a cash position of $136.1 million, projected to fund operations until Q1 2024. R&D expenses increased to $16.9 million, driven by clinical trials and facility expansions. The net loss was $23.8 million. In-house clinical manufacturing is now operational, supporting the IND submission for VCAR33 in H1 2023. The company plans to present initial clinical data for VOR33 by the end of 2022 and has received ATMP status from EMA for VOR33 and VCAR33.
Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences. Key events include:
- Credit Suisse 31st Annual Healthcare Conference: Virtual presentation on November 8, 2022.
- Stifel 2022 Healthcare Conference: Fireside chat on November 16, 2022, at 10:20 am EST in New York, NY.
- Jefferies London Healthcare Conference: Fireside chat on November 17, 2022, at 3:15 pm GMT in London, UK.
Webcasts of these events will be available on Vor Bio's investor section.
Vor Bio (Nasdaq: VOR) has appointed Dr. Eyal C. Attar as Chief Medical Officer, bringing over 20 years of clinical experience, particularly in hematologic malignancies. The company anticipates important clinical trial data for VOR33 later this year, alongside an IND submission for VCAR33ALLO planned for early next year. Dr. Attar's expertise in AML and prior roles at Aprea Therapeutics and Agios Pharmaceuticals are expected to enhance Vor Bio's clinical development capabilities. An inducement equity award of 364,000 stock options was granted to Dr. Attar as part of his appointment.
Vor Bio (Nasdaq: VOR) presented promising preclinical data on its novel base editing platform for hematopoietic stem cell (HSC) engineering at the ESGCT Annual Congress in Edinburgh. Their research showcased the successful multiplex deletion of myeloid antigens CD33 and CLL-1, which maintained HSC function and exhibited long-term engraftment without genotoxic risks. This innovative approach is aimed at improving safety and efficacy for treating acute myeloid leukemia (AML), addressing significant challenges in current therapies.
Vor Bio has opened a new in-house clinical manufacturing facility in Cambridge, MA, to enhance the production of engineered hematopoietic stem cells (eHSCs) and CAR-T therapies targeting blood cancers. This facility aims to improve integration across teams, reduce manufacturing time and cost, and boost operational efficiency for ongoing clinical trials. The facility includes four cleanrooms and is designed to comply with Good Manufacturing Practice (cGMP) standards. The company plans to support the IND submission for VCAR33 by mid-2023.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced its participation in several investor conferences in September 2022.
The events include:
- Morgan Stanley 20th Annual Global Healthcare Conference: September 12, 2022, at 4:50 pm ET in New York, NY
- H.C. Wainwright 24th Annual Global Investment Conference: September 14, 2022, at 8:30 am ET in New York, NY
- Baird’s 2022 Global Healthcare Conference: September 14, 2022, at 10:50 am ET in New York, NY
- Jefferies Cell and Genetic Medicine Summit: September 30, 2022, in New York, NY
A live webcast of the Morgan Stanley chat will be available on vorbio.com.
Vor Bio (Nasdaq: VOR) announced its Q2 2022 financial results, reporting a net loss of $21.7 million, up from $18.4 million in Q2 2021. Cash reserves of $151.1 million will support operations into Q1 2024. The company is on track to share initial clinical data for its lead candidate VOR33 in Q4 2022, which aims to provide a treatment for acute myeloid leukemia (AML). The operational in-house manufacturing facility in Cambridge, MA is also expected to begin operations in Q4 2022, enhancing production capabilities for future therapies.